BASEL, Switzerland, July 7, 2021, Basel, Switzerland – Noema Pharma (‘Noema”) AG, a Swiss clinical-stage company targeting orphan neurological disorders, will host a key opinion leader (KOL) webinar on seizures in tuberous sclerosis complex (TSC) on Tuesday, July 20, 2021 at 4pm CET / 10am Eastern Time.
The webinar will feature a presentation by Dr Ali Mostajelean MD, UCSF Benioff Children’s Hospital Oakland, who will discuss the current treatment landscape and unmet medical need in treating patients with seizures in TSC (Tuberous Sclerosis Complex). Dr. Mostajelean will be available to answer questions following the formal presentations.
Noema’s management team will also provide an update on their lead compound NOE-101, an mGluR5 inhibitor, which is about to enter Phase 2b in two indications: persistent seizures in Tuberous Sclerosis Complex (TSC) and severe pain in Trigeminal Neuralgia (TN).
NOE-101 mGluR5 NAM, is a highly selective, potent, and cell penetrant negative allosteric modulator of mGlu5 receptors for the treatment of seizures associated with tuberous sclerosis complex (TSC) and for the management of pain associated with Trigeminal Neuralgia (TN). The compound has been through extensive clinical testing and already has a large safety database with 350 adults and 70 children and adolescents.
To register for the webinar, please click here.
About Dr. Mostajelean
Dr. Mostajelean directs the clinical epilepsy service and the Jack and Julia Tuberous Sclerosis Clinic at UCSF Benioff Children’s Hospital Oakland, where he focuses upon drug resistant epilepsy across various underlying etiologies. Dr Mostajelean graduated with honors from the University of California Los Angeles, earning a bachelor’s of science in Neuroscience. He then earned his medical degree at Drexel Medical College. Dr. Mostajelean is currently dual board certified in Child Neurology and Epilepsy with six years of post medical school residency and fellowship training spanning Children’s Hospital of Los Angeles and Stanford University. In an advisory role, Dr Mostajelean bridges his background in basic neuroscience and a high volume, tertiary care practice to provide unique perspectives upon drug discovery and to better align the needs and goals of clinical compound development at every stage.
About Noema Pharma
Noema Pharma (www.noemapharma.com) is a Swiss-based company targeting orphan neurological disorders characterized by imbalanced neuronal networks. The company is developing four mid-clinical-stage therapeutic products in-licensed from Roche and with strong safety packages. Lead product NOE-101, an mGluR5 inhibitor, is Phase 2b-ready for two indications: persistent seizures in Tuberous Sclerosis Complex (TSC) and severe pain in Trigeminal Neuralgia (TN). NOE-105, a PDE10A inhibitor, is in preparation for Phase 2b testing to treat Tourette Syndrome. The Company is undertaking validation studies in undisclosed indications for two additional clinical-stage assets, NOE-109, an mGluR2/3 inhibitor, and NOE-115, a triple re-uptake inhibitor. Noema Pharma was founded with the leading venture capital firm Sofinnova Partners. Investors include Polaris Partners, Gilde Healthcare, Invus and Biomed Partners.
DISCLAIMER – CERTIFICATION
Practicing physicians are not authorized to attend this event. This event, sponsored by Noema Pharma, is not to be considered as a promotion of Noema’s technology or Noema’s compounds, nor as a solicitation to use its products and none of Noema’s investigational drugs have been reviewed or approved by health authorities.
To register for this event, you will be requested that you have read and understand the Disclaimer and that you are not a practicing physician
Chief Executive Officer
Investors & Media
LifeSci Advisors – Guillaume van Renterghem
+41 (0) 76 735 01 31